Churchill Capital Corp XI - Class A Ordinary Shares (CCXI)

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR --

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

  ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model --

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

The biotech run off a June bottom is great — until you realize you could've netted more.

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment

The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord Stream suspension of natural gas to Germany.

According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

These names are benefitting from M&A, clinical data and promising regulatory actions.

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and earnings reports become available.

The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.

The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring biotech small cap performance.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific."

 

  ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.49.

With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Upgrades